3月24日 - ** 经纪公司杰富瑞（Jefferies）开始对眼科医疗设备公司Rxsight（RXST.O）进行评级，给予“买入”评级，目标价定为50美元
** 新目标价较 股票最后收盘价高出两倍多
** 券商称RXST的竞争优势很强，未来5年增长潜力巨大，竞争压力很小
** 认为公司用于白内障手术的轻质可调节镜片(LALs) 具有上升空间；并称该手术对外科医生来说利润丰厚
**LALs与传统镜片不同，可在植入后进行调节
** 10家券商中有8家给予该股票“买入”或更高评级，2家给予“持有”评级，平均目标价为43美元——伦敦证券交易所集团数据
** RXST股票在过去12个月下跌51%
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.